Healthcare Industry News: GPC Biotech
News Release - February 12, 2007
Promedior Adds to Management TeamMALVERN, Pa.--(HSMN NewsFeed)--Promedior (formerly Medior), a product-focused biotech company developing novel therapeutics for the treatment of fibrotic disorders and diseases, announced today that David P. Hesson, Ph.D., former Director of Project Management & In-Licensing at GPC Biotech, has been named Vice President of Product Development. The company also announced that Mark L. Lupher, Jr., Ph.D., former Director of Drug Discovery at ICOS Corporation has been named Vice President of Drug Discovery.
As Vice President of Product Development, Dr. Hesson will be responsible for all aspects of drug development including chemistry, manufacturing and controls as well as preclinical pharmacology and toxicology needed to move Promedior's agents into clinical trials and onto commercialization. During his time with GPC Biotech, Dr. Hesson was responsible for the worldwide Phase III satraplatin pivotal trial and US & EU regulator filings. His 30 year career includes professional positions at Neuron Therapeutics, Oread, Symphony Pharmaceuticals and DuPont Merck Pharmaceuticals. Dr. Hesson holds a Ph.D. in Chemistry, from the Massachusetts Institute of Technology. Following his doctorate, Dr. Hesson conducted post-doctoral work in Chemistry as a National Institutes of Health Fellow at Harvard University under Dr. R. B. Woodward.
"Dave's deep and broad experience in drug development spanning across numerous therapeutic areas is a perfect background to move our novel agents into the clinic," said Tim Pelura, Ph.D., President and CEO of Promedior. "He has literally dozens of successful development programs including both small molecules and biologics under his belt. In addition, Dr. Hesson is very experienced in patent preparation, strategy, prosecution and portfolio management, obviously an important aspect of any emerging company."
As Vice President of Drug Discovery, Dr. Lupher will have responsibility for all internal and external discovery efforts as well as in-licensing activities. Dr. Lupher has wide-ranging experience in the discovery and development of both biologic and small molecule drug candidates for the treatment of inflammatory and fibrotic diseases. As Associate Director of Drug Discovery at ICOS Corporation, he pioneered the discovery of novel anti-fibrotic therapeutics and the development of the fibrotic disease therapeutic area. In addition, Dr. Lupher was responsible for a new Evaluation and Alliance group to initiate and manage research licensing and collaborations with peer biotechnology companies. Dr. Lupher has held various R&D positions at biopharmaceutical companies such as ICOS Corporation and Immunex. Dr. Lupher holds a Ph.D. in Immunology from the Division of Medical Sciences at Harvard University and was a Post-Doctoral fellow at the Brigham and Women's Hospital.
"Promedior is especially happy to have an individual of Mark's credentials join the management team," said Tim Pelura, Ph.D., President and CEO of Promedior. "There are few industry professionals that can be considered experts in our therapeutic area of fibrosis. Not only has Mark established himself scientifically in the area but he has also done much to bring experts together at nationally recognized conferences to discuss the leading edge of the field. With the addition of Drs. Lupher and Hesson, Promedior is well positioned to be the leader in the fibrosis arena."
About the Company
Promedior is a product-focused biopharmaceutical company developing novel therapeutics for the treatment of fibrotic disorders and diseases. Fibrosis is a leading cause of morbidity and mortality and a key component of multiple diseases affecting millions of people worldwide including all organ systems. Fibrosis is inappropriate scar tissue which replaces normal tissue and leads to organ failure. Promedior has license to novel biology and is developing innovative new compounds and anti-fibrotic therapies based on that biology. With leadership and advisors on the cutting edge of fibrosis research, Promedior is positioned to be a leader in the development of new therapies for fibrotic disorders and diseases. The management team has broad and deep drug development expertise, including global pharmaceutical development, regulatory affairs, clinical development, drug manufacturing and commercialization. Our scientific advisory board is comprised of prominent fibrosis experts from the nation's leading medical centers and universities. To date, Promedior has raised $7 million in a Series A private equity financing co-led by Polaris Venture Partners and Morgenthaler Ventures and joined by HealthCare Ventures and Easton Capital.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.